|1.||Hoffmann, Ralf: 5 articles (04/2014 - 07/2012)|
|2.||Berthold, Nicole: 4 articles (04/2014 - 07/2012)|
|3.||Knappe, Daniel: 4 articles (01/2013 - 07/2012)|
|4.||Fritsche, Stefanie: 3 articles (01/2013 - 07/2012)|
|5.||Alber, Gottfried: 3 articles (01/2013 - 07/2012)|
|6.||Czihal, Patricia: 2 articles (01/2013 - 07/2012)|
|7.||Moret, Francesca: 1 article (07/2015)|
|8.||Reddi, Elena: 1 article (07/2015)|
|9.||Gobbo, Marina: 1 article (07/2015)|
|10.||Al-Mekhlafi, Moath: 1 article (01/2013)|
01/01/2013 - "Most recently, we showed that the 18-residue-long peptide Api88, an optimized version of apidaecin 1b, was efficient in two different animal infection models using the pathogenic Escherichia coli strains ATCC 25922 and Neumann, with a promising safety margin. "
01/01/2013 - "Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens."
07/20/2012 - "Starting from the antibacterial peptide apidaecin 1b, we have optimized the sequence to treat systemic infections with the most threatening human pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. "
04/01/2008 - "lactis may provide a clue to facilitate the widespread application of apidaecin in the control and prevention of gram-negative bacteria infections of human and animals."
01/01/2013 - "Apidaecin peptides are produced by the honeybee Apis mellifera as a major part of its non-specific defense system against infections. "
07/01/2015 - "Here we have investigated the potential of three AMPs, namely apidaecin 1b (Api), magainin 2 (Mag) and buforin II (Buf), as carriers of drugs for cancer cells by using the hydrophobic photosensitiser 5-(4-carboxyphenyl)-10,15,20-triphenylporphyrin (cTPP) as the drug model, conjugated to the N-terminus of the peptides. "
|3.||Muscle Cramp (Cramp)
10/01/2012 - "Furthermore, the tested oncocin and apidaecin derivatives do not modulate the immune response after LPS stimulation, whereas CRAMP shows a reduction of the LPS-mediated immune response as expected. "
10/01/2012 - "Therefore, we studied oncocin and apidaecin derivatives for their effects on murine dendritic cells (DC) and macrophages and compared them with well-known immunomodulatory activities of murine cathelicidin-related antimicrobial peptide (CRAMP). "
|4.||Bacterial Infections (Bacterial Infection)
|4.||CAP18 lipopolysaccharide-binding protein (Bac4)